NCT04074174View on ClinicalTrials.gov

Research Study to Investigate the Effect of NNC0174-0833 on a Birth Control Pill in Women Who Are Not Able to Become Pregnant

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

September 12, 2019

Primary Completion Date

March 6, 2020

Study Completion Date

March 6, 2020

Conditions
OverweightObesity
Interventions
DRUG

NNC0174-0833

NNC0174-0833 administered s.c. (subcutaneously, under the skin) once weekly for 12 weeks

DRUG

Oral contraceptive (OC) tablets

1 tablet daily on days 1-8 and days 79-86

DRUG

Acetaminophen

Single dose of acetaminophen as part of a standardised meal on day 1 and day 79

Trial Locations (1)

H3P 3P1

Novo Nordisk Investigational Site, Montreal

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY